|
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients Clinical research trials and Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients. Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients  Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
For Condition: Multiple Sclerosis
Status: No longer recruiting
Sponsor(s): Avanir Pharmaceuticals ,
Synopsis: Pseudobulbar Affect is a condition characterized by frequent episodes of laughing and crying out of proportion. Other terms used to describe this condition include emotional lability, emotionalism, emotion incontinence, emotional discontrol, excessive emotionalism and pathological laughing and crying. AVP-923 is a new experimental drug that may assist in the reduction of uncontrolled episodes. This study will test the safety and efficacy of AVP-923 in the treatment of MS patients suffering from pseudobulbar affect.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/68 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - 18 to 68 years of age - Confirmed diagnosis of Multiple Sclerosis - Clinical history of pseudobulbar affect Exclusion Criteria: - Sensitivity to quinidine or opiate drugs - Recent diagnosed within 2 months with Multiple Sclerosis - Patient on anti-depressants - Patient with liver or kidney disease - Patient with hypotension
Total Enrollment: 96
Location and Contact Information:
Raleigh Neurology Associates, P.A.
Raleigh, North Carolina, 27607
United States
Neurological Associates of Delaware Valley
Upland, Pennsylvania, 19013
United States
Neurology and Neurosurgery Associates of Tacoma
Tacoma, Washington, 98405
United States
Upstate Clinical Research
Albany, New York, 12205
United States
Swedish Medical Center
Seattle, Washington, 98122
United States
Hospital for Joint Diseases - MS Care Center
New York City, New York, 10003
United States
Radiant Research Alexian Brothers
Elk Grove Village, Illinois, 60007
United States
NeuroCare Center, Inc.
Canton, Ohio, 44718
United States
Neurological Associates, P.C.
Lincoln, Nebraska, 68506
United States
DENT Neurologic Group L.L.P.
Amherst, New York, 14266
United States
Consultants in Neurology LTD
Northbrook, Illinois, 60062
United States
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, 20037
United States
Advanced Neurology Specialists
Great Falls, Montana, 59405
United States
Neurology & Headache Specialist of Atlanta, L.L.C.
Decatur, Georgia, 30033
United States
Leheigh Valley Neurosciences and Pain Research Center
Allentown, Pennsylvania, 18103
United States
Barrow Neurological Institute
Phoenix, Arizona, 85013
United States
Institute for Human Performance
Syracuse, New York, 13210
United States
Westmorland Neurology
Greensburg, Pennsylvania, 15601
United States
Neurological Associates
Ft. Lauderdale, Florida, 33334
United States
FACH-UHC Department of Neurological Services
Burlington, Vermont, 05401
United States
Additional Information:
Study ID Numbers: 02-AVR-106;
Study Start Date: December 2002
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00050232
Other Multiple Sclerosis Studies:
1. Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
2. Auditory Function in Patients With and Without Multiple Sclerosis
3. Improving Memory in Patients with Multiple Sclerosis
4. Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis
5. Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis
Related Studies:
Other Multiple Sclerosis Clinical Trials
Other Arizona Clinical Trials
Other Phoenix Clinical Trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
|
|
|
|
|
|
|
|
